Sponsors (3)
The bill improves readiness and reduces drug‑shortage risks for patients and health systems by creating an essential medicines list, supply‑chain mapping, and reporting—but does so at the cost of new federal and industry compliance expenses, potential market distortions, and risks to proprietary or security‑sensitive information.
Patients with chronic conditions and other medicine-dependent Americans will face fewer unexpected drug shortages because the bill creates and regularly updates an essential medicines list and requires supply‑chain mapping and analytics to identify vulnerabilities.
Hospitals, health systems, and purchasers will get clearer, predictable guidance (updated list and supplier risk information) to prioritize procurement, plan contingencies, and diversify sourcing.
Federal policymakers, Congress, and emergency planners will receive regular, evidence‑based reports and improved interagency coordination (including alignment with cybersecurity authorities), strengthening national preparedness and speeding regulatory responses during shortages.
Taxpayers and federal agencies will face increased administrative and program costs (data collection, analysis, reporting, possible procurement or manufacturing incentives), raising federal spending and compliance burdens.
Detailed supply‑chain reporting and broader interagency data sharing risk exposing proprietary, sensitive, or security‑critical information—if mishandled this could harm companies and national security.
Publicizing an essential medicines priority list and supplier risks could create market distortions (surge buying, reduced demand for non‑listed drugs) and lead to procurement rules that limit local purchasing flexibility for providers and payers.
Based on analysis of 6 sections of legislative text.
Directs HHS to create/update an Essential Medicines List and to assess, map, and report on supply‑chain vulnerabilities for those drugs to inform mitigation actions.
Official title: To improve coordination of Federal efforts to identify and mitigate health and national security risks through maintaining a list of essential medicines, conducting a risk assessment of essential medicine supply chains, and creating a monitoring system to map essential medicine supply chains using data analytics.
Introduced June 26, 2025 by Doris Matsui · Last progress June 26, 2025
Creates and maintains a federal “Essential Medicines List” and directs HHS to analyze, map, and report on the U.S. supply chains for those medicines and their active pharmaceutical ingredients. The law requires regular risk assessments, public reporting to Congress, interagency data sharing (with protections for trade secrets), and cybersecurity safeguards to identify vulnerabilities that could lead to shortages or national security risks. The Secretary of HHS must update the list quickly (first update within 180 days), review it at least every two years, complete supply‑chain risk assessments and visual mapping with analytics, and provide recurring reports to Congress to support mitigation actions including use of Defense Production Act authorities.